Russian military forces struck the Darnitsa pharmaceutical plant in Kyiv. This was reported on September 23, 2026, by RBC-Ukraine, citing the Facebook page of Kateryna Zagoriy — a member of the Strategic Council of the pharmaceutical company Darnitsa and co-founder of the Zagoriy Foundation. The company itself confirmed the fact of the attack, but as of the time of the statement's publication, it did not disclose information about the nature of the damage or the consequences of the strike.
Company statement: "No workers killed"
In her address, Kateryna Zagoriy stated: "For security reasons and until the work of the competent authorities is completed, we are not commenting on the details of the nature of the damage or its consequences. At this time, we can confirm that no workers have been killed." Thus, the company limited itself to a minimal confirmation of the fact of the strike and declined to provide any additional details while the relevant agencies are working at the scene. Zagoriy also urged the public not to publish photographs or videos from the scene of the incident, citing security considerations.
What is known about the damage
At the time of preparing this article, the extent and nature of the damage to Darnitsa's production facilities remain unknown. The company explicitly stated that it will not comment on the details until the work of the competent authorities is completed. This means that the assessment of the damage — whether it involves workshops, storage facilities, or logistics infrastructure — will be provided at a later date. The lack of public information on the scale of the destruction makes it impossible at this time to assess how the strike may affect the enterprise's production capacity in the short term.
Darnitsa: one of Ukraine's largest pharmaceutical producers
Darnitsa is a Ukrainian pharmaceutical company headquartered in Kyiv, producing more than 200 brands of medicinal products. The company's range covers key therapeutic areas: cardiology, neurology, pain treatment, and others. The drugs are produced in various dosage forms — tablets, capsules, ampoules, drops, and others. Among the company's best-known trademarks are Citramon-Darnitsa, Paracetamol-Darnitsa, Analgin-Darnitsa, Mefenamin, Darfen Express, Captopress-Darnitsa, Spironolactone-Darnitsa, Septefril-Darnitsa, Medichronal-Darnitsa, Darsil, and Adrenaline-Darnitsa. A strike on an enterprise of this scale potentially affects the availability of basic medicines for a significant portion of the population.
Context: repeated strikes on pharmaceutical production and market risks
This is not the first strike on the Darnitsa plant this year. In June 2026, Russian military forces had already struck the pharmaceutical enterprise in Kyiv. Thus, in less than three months, the plant has been subjected to at least two attacks. Recently, in a comment to RBC-Ukraine, company representatives assessed the risk of a shortage of medicines on the domestic market and commented on possible changes in drug prices against the backdrop of ongoing Russian attacks on pharmaceutical production facilities. Repeated strikes on infrastructure producing more than 200 types of medicines create a systemic risk to the supply of basic medications to the population.
Reaction and calls for restraint
In addition to the official confirmation of the fact of the strike, the company Darnitsa, through Kateryna Zagoriy, issued a public appeal not to disseminate photographs and videos from the scene of the incident. This is standard practice for enterprises where competent authorities are working: the publication of visual materials may complicate the investigation and create additional security risks. Detailed information on the consequences of the strike, including the damage assessment and the timelines for restoring production processes, is expected after the work of the relevant agencies is completed.
